期刊
JOURNAL OF ETHNOPHARMACOLOGY
卷 128, 期 3, 页码 615-622出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.jep.2010.02.004
关键词
23-Hydroxybetulinic acid; Synergism; Doxorubicin; Combination chemotherapy; Pharmacokinetics
资金
- China National Nature Science Foundation [30572228, 30630076]
- China National 11th 5-year technology supporting program [2006BA108B04-05]
- China National Natural Science Foundation [30801411]
- China Creation of New Drugs Key Technology [2009ZX09103]
Ethnopharmacological revelance: Pulsatilla chinensis (Bunge) Regel has been used as adjuvant in chemotherapy in traditional Chinese medicine. 23-Hydroxybetulinic acid, an isolated pentacyclic triterpene, is the major active constituent of Pulsatilla chinensis (Bunge) Regel. Aim of this study: To evaluate the combinational anticancer effect of 23-hydroxybetulinic acid and doxorubicin in vitro and in vivo. Materials and methods: The effect of combination treatment with 23-hydroxybetulinic acid and doxorubicin was evaluated with a quantitative combination index method based on the median-effect analysis in various cancer cell lines. And in vivo efficacy of combination chemotherapy was also evaluated using ICR mice bearing sarcoma 180 carcinoma tumors. Results: 23-Hydroxybetulinic acid showed a synergistic cytotoxic effect on multiple cancer cell lines by combined use with doxorubicin. In vivo studies further demonstrated that co-administration of 23-HBA significantly improved the sensitivity of the tumor to doxorubicin through increasing intra-tumor doxorubicin concentration and inhibiting doxorubicin-induced up-regulation of P-gp in tumor. Conclusion: These results suggest that the combined therapy with 23-hydroxybetulinic acid and doxorubicin may be a new promising strategy to promote the clinical chemotherapy, which needs further verification. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据